COVID-19 Medical Countermeasures: Intellectual Property and Affordability [March 18, 2020] [open pdf - 642KB]
From the Document: "Federal agencies and private industry have begun efforts to develop and test medical countermeasures (such as antiviral treatments and vaccines) to combat COVID-19 [coronavirus disease 2019], the disease caused by the novel coronavirus SARS-CoV-2 [severe acute respiratory syndrome coronavirus 2]. [...] This Sidebar reviews several intellectual property (IP) rights provisions under current law that the federal government could use to try to ensure that COVID-19 countermeasures are accessible and affordable. Other actions that the federal government might hypothetically take--such as additional spending, production by federal agencies, governmental negotiation, or direct price controls--are beyond the scope of this Sidebar, in that such measures do not implicate IP rights and may require additional legislative action beyond the 'current law' referenced in CPRSA [Coronavirus Preparedness and Response Supplemental Appropriations Act]."
CRS Legal Sidebar, LSB10422
Congressional Research Service: https://crsreports.congress.gov/